152
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Correlation Between Higher Cumulative Dose of Cisplatin for Concurrent Chemoradiation and Acute Kidney Disease Incidence Among Nasopharyngeal Carcinoma Patients: A Comparative Study

ORCID Icon, ORCID Icon &
Pages 10527-10539 | Published online: 31 Dec 2021

References

  • Kentjono WA. Perkembangan terkini penatalaksanaan karsinoma nasofaring (Current updates on the treatment of nasopharyngeal carcinoma). Maj Kedokteran Trop Indones; 2003.
  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
  • Fles R, Wildeman MA, Sulistiono B, Haryana SM, Tan IB. Knowledge of general practitioners about nasopharyngeal cancer at the Puskesmas in Yogyakarta, Indonesia. BMC Med Educ. 2010;10. doi:10.1186/1472-6920-10-81
  • Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378. doi:10.1016/j.ejphar.2014.07.025
  • Reiss KA, Hilary Calvert A, O’Dwyer PJ. Platinum analogs. In: Devita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. Lippincott Williams & Wilkins; 2018.
  • Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310–1317. doi:10.1200/JCO.1998.16.4.1310
  • Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21:631–637. doi:10.1200/JCO.2003.06.158
  • Chan ATC, Leung SF, Ngan RKC, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005;97(7):536–539. doi:10.1093/jnci/dji084
  • Loong HH, Ma BBY, Leung SF, et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol. 2012;104(3):300–304. doi:10.1016/j.radonc.2011.12.022
  • Lv JW, Qi ZY, Zhou GQ, et al. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy. Cancer Sci. 2018;109(3):751–763. doi:10.1111/cas.13474
  • Peng H, Chen L, Zhang Y, et al. Prognostic value of the cumulative cisplatin dose during concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a prospective Phase III Clinical Trial. Oncologist. 2016;21(11):1369–1376. doi:10.1634/theoncologist.2016-0105
  • Danchaivijitr P, Ngamphaiboon N, Jiarpinitnun C, Sirachainan E, Pattaranutaporn P, Setakornnukul J. An optimal cumulative dose of cisplatin in chemoradiotherapy as a definitive treatment for non-metastatic nasopharyngeal carcinoma: a retrospective multicenter study. Ann Oncol. 2016;27(Supplement 6):vi344. doi:10.1093/annonc/mdw376.50
  • National Comprehensive Cancer Network. NCCN guidelines Version 2.2020 head and neck cancers. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®); 2020.
  • Dabholkar M, Bostick-bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst. 1992;84(19):1512–1517. doi:10.1093/jnci/84.19.1512
  • Florea AM, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers. 2011;3:1351–1371. doi:10.3390/cancers3011351
  • Vincent IS, Okusa MD. Biology of renal recovery: molecules, mechanisms, and pathways. Nephron Clin Pract. 2014;127:10–14. doi:10.1159/000363714
  • Driessen CML, Uijen MJM, Van Der Graaf WTA, et al. Degree of nephrotoxicity after intermediate- or high-dose cisplatin-based chemoradiotherapy in patients with locally advanced head and neck cancer. Head Neck. 2016;38:E1575–E1581. doi:10.1002/hed.24281
  • Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD. Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol. 2016;11:1173–1179. doi:10.2215/CJN.08070715
  • Chawla LS, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the acute disease quality initiative (ADQI) 16 workgroup. Nat Rev Nephrol. 2017;13(4):241–257. doi:10.1038/nrneph.2017.2
  • Salahudeen AK, Doshi SM, Pawar T, Nowshad G, Lahoti A, Shah P. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol. 2013;8(3):347–354. doi:10.2215/CJN.03530412
  • Prasaja Y, Sutandyo N, Andrajati R. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia. Asian Pacific J Cancer Prev. 2015;16(3):1117–1122. doi:10.7314/APJCP.2015.16.3.1117
  • Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994–1007. doi:10.1038/sj.ki.5002786
  • Peres LA Lbert B, da Cunha ADA. Acute nephrotoxicity of cisplatin: molecular mechanisms. J Bras Nefrol ‘Orgão of Soc Bras e Latino-Americana Nefrol. 2013;35(4):332–340.
  • Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH. High dose Cis‐platinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis. Cancer. 1977;39:1372–1381. doi:10.1002/1097-0142(197704)39:4<1372::AID-CNCR2820390404>3.0.CO;2-J
  • Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins. 2010;2(11):2490–2518. doi:10.3390/toxins2112490
  • Ruggiero A, Rizzo D, Trombatore G, Maurizi P, Riccardi R. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not? Cancer Chemother Pharmacol. 2016;77(1):19–26. doi:10.1007/s00280-015-2913-6
  • Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy special interest group on cancer care. Cancer Chemother Pharmacol. 2008;61:903–909. doi:10.1007/s00280-008-0711-0
  • Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett. 2015;237:219–227. doi:10.1016/j.toxlet.2015.06.012
  • Wei W, Huang Z, Li S, et al. Pretreatment Epstein-Barr virus DNA load and cumulative cisplatin dose intensity affect long-term outcome of nasopharyngeal carcinoma treated with concurrent chemotherapy: experience of an institute in an endemic area. Oncol Res Treat. 2014;37(3):88–95. doi:10.1159/000360178
  • Forni LG, Darmon M, Ostermann M, et al. Renal recovery after acute kidney injury. Intensive Care Med. 2017;43:855–866. doi:10.1007/s00134-017-4809-x
  • Ferenbach DA, Bonventre JV. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat Rev Nephrol. 2015;11(5):264–276. doi:10.1038/nrneph.2015.3
  • Faig J, Haughton M, Taylor RC, et al. Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. Am J Clin Oncol Cancer Clin Trials. 2018;41:432.
  • Kellum JA, Lameire N, Aspelin P, et al. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–38.
  • Hsu CK, Wu IW, Chen YT, et al. Acute kidney disease stage predicts outcome of patients on extracorporeal membrane oxygenation support. PLoS One. 2020;15(4):1–11. doi:10.1371/journal.pone.0231505
  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.21660
  • Nainani P, Nagpal N, Agrawal M, Paliwal A. Sex hormones in gender-specific risk for head and neck cancer: a review. J Int Soc Prev Community Dent. 2014;4:1. doi:10.4103/2231-0762.144557
  • Faiza S, Rahman S, Asri A. Karakteristik klinis dan patologis karsinoma nasofaring di bagian THT-KL RSUP Dr.M.Djamil Padang (Clinical and pathological characteristics of nasopharingeal carcinoma in the otorhinolaryngology department of Dr. M. Djamil Hospital, Padang). J Kesehat Andalas. 2016;5(1):90–96.
  • Adham M, Kurniawan AN, Muhtadi AI, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer. 2012;31:185–196. doi:10.5732/cjc.011.10328
  • Patimarattananan T, Nongnuch A, Pattaranutaporn P, Unwanatham N, Jiarpinitnun C, Ngamphaiboon N. Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin. Support Care Cancer. 2021;29(2):877–887. doi:10.1007/s00520-020-05566-y
  • Mizushima Y, Nagahama H, Yokoyama A, Morikage T, Yano S. Studies on nephrotoxicity following a single and repeated administration of cis-Diamminedichloroplatinum (CDDP) in rats. Tohoku J Exp Med. 1987;151:129–135. doi:10.1620/tjem.151.129
  • Tezcan S, Izzettin FV, Sancar M, Yumuk PF, Turhal S. Nephrotoxicity evaluation in outpatients treated with cisplatin-based chemotherapy using a short hydration method. Pharmacol Pharm. 2013;04:296–302. doi:10.4236/pp.2013.43043
  • Sharp CN, Siskind LJ. Developing better mouse models to study cisplatin-induced kidney injury. Am J Physiol Renal Physiol. 2017;313:F835–F841. doi:10.1152/ajprenal.00285.2017
  • Morgan KP, Snavely AC, Wind LS, et al. Rates of renal toxicity in cancer patients receiving cisplatin with and without mannitol. Ann Pharmacother. 2014;48(7):863–869. doi:10.1177/1060028014533303
  • Moon HH, Seo KW, Yoon KY, Shin YM, Choi KH, Lee SH. Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. World J Gastroenterol. 2011;17(30):3510-3517. doi:10.3748/wjg.v17.i30.3510
  • Hrushesky WJM, Shimp W, Kennedy BJ. Lack of age-dependent cisplatin nephrotoxicity. Am J Med. 1984;76:579–584. doi:10.1016/0002-9343(84)90280-8
  • Mizuno T, Ishikawa K, Sato W, et al. The risk factors of severe acute kidney injury induced by cisplatin. Oncol. 2013;85(6):364–369. doi:10.1159/000356587
  • Loh JM, Tran AL, Ji L, et al. Baseline glomerular filtration rate and cisplatin- induced renal toxicity in urothelial cancer patients. Clin Genitourin Cancer. 2018;16(1):90–98.e1. doi:10.1016/j.clgc.2017.08.016
  • Andronesi AG, Tanase AD, Sorohan BM, et al. Incidence and risk factors for acute kidney injury following autologous stem cell transplantation for multiple myeloma. Cancer Med. 2019;8(6):3278–3285. doi:10.1002/cam4.2187
  • Gundog M, Basaran H, Bozkurt O, Eroglu C. A comparison of cisplatin cumulative dose and cisplatin schedule in patients treated with concurrent chemo-radiotherapy in nasopharyngeal carcinoma. Braz J Otorhinolaryngol. 2020;86(6):676–686. doi:10.1016/j.bjorl.2019.04.008
  • Peng H, Chen L, Li WF, et al. The cumulative cisplatin dose affects the long-term survival outcomes of patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy. Sci Rep. 2016;6:1–8. doi:10.1038/s41598-016-0001-8